Hummingbird Bioscience Funding: $125M Raised, Series C
Hummingbird Bioscience is based in Singapore, Singapore. It has raised $125M in total funding. Latest round: Series C.
Hummingbird Bioscience funding overview
Hummingbird Bioscience is based in Singapore, Singapore. Hummingbird Bioscience has raised $125M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series C announced in May 2021. The round record for Hummingbird Bioscience runs through 2021; nothing later has been disclosed. Investors on record include Novo Holdings, Frazier Healthcare Partners, Octagon Capital, EDBI, Amgen Ventures, DROIA Ventures and 10 others. 16 distinct backers are named across the disclosed rounds.
Frequently asked about Hummingbird Bioscience funding
How much has Hummingbird Bioscience raised?
Hummingbird Bioscience has raised $125M in total disclosed funding across the rounds on record.
Who has invested in Hummingbird Bioscience?
Novo Holdings, Frazier Healthcare Partners, Octagon Capital, EDBI, Amgen Ventures, DROIA Ventures are named among the investors backing Hummingbird Bioscience.
What was the latest Hummingbird Bioscience funding round?
The most recent disclosed round is a Series C, announced in May 2021.
Where is Hummingbird Bioscience based?
Hummingbird Bioscience is based in Singapore, Singapore.
When did Hummingbird Bioscience last raise?
The last disclosed Hummingbird Bioscience round closed in May 2021 at Series C.
Totals shown for Hummingbird Bioscience aggregate every disclosed round on file. To see how that compares, browse the companies in Singapore and the investors behind them below.
